Scarica l'app Stockscreener
0.8879
0.05%
-0.0004
Dopo l'orario di chiusura:
.87
-0.0179
-2.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SCYX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.8883
Aprire:
$0.88
Volume 24 ore:
261.56K
Relative Volume:
0.46
Capitalizzazione di mercato:
$39.66M
Reddito:
$20.60M
Utile/perdita netta:
$-8.61M
Rapporto P/E:
-6.4294
EPS:
-0.1381
Flusso di cassa netto:
$-5.28M
1 W Prestazione:
+6.02%
1M Prestazione:
+18.50%
6M Prestazione:
+11.50%
1 anno Prestazione:
-6.54%
Intervallo 1D:
$0.85
$0.90
Intervallo di 1 settimana:
$0.762
$0.92
Portata 52W:
$0.565
$1.31
Scynexis Inc Stock (SCYX) Company Profile
Nome
Scynexis Inc
Settore
Telefono
201-884-5485
Indirizzo
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Compare SCYX vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
0.8879 | 39.66M | 20.60M | -8.61M | -5.28M | -0.1381 |
TAK
Takeda Pharmaceutical Co Adr
|
18.74 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
117.94 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.93 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.08 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
564.81 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-01-22 | Iniziato | Guggenheim | Buy |
| 2021-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-11 | Aggiornamento | Needham | Hold → Buy |
| 2018-06-27 | Iniziato | Maxim Group | Buy |
| 2017-10-24 | Iniziato | Guggenheim | Buy |
| 2017-07-10 | Iniziato | ROTH Capital | Buy |
| 2017-05-09 | Downgrade | Needham | Buy → Hold |
| 2017-03-03 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-20 | Iniziato | H.C. Wainwright | Buy |
| 2016-10-07 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2016-10-03 | Ripresa | Brean Capital | Buy |
| 2016-08-17 | Iniziato | Guggenheim | Buy |
| 2016-08-09 | Reiterato | Needham | Buy |
| 2016-08-09 | Aggiornamento | WBB Securities | Speculative Buy → Buy |
| 2016-03-28 | Iniziato | Brean Capital | Buy |
| 2015-12-29 | Iniziato | WBB Securities | Speculative Buy |
| 2015-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2015-06-10 | Iniziato | Needham | Buy |
| 2014-05-29 | Iniziato | Canaccord Genuity | Buy |
| 2014-05-29 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Scynexis Inc Borsa (SCYX) Ultime notizie
Scynexis CEO Angulo Gonzalez buys $100k in shares By Investing.com - Investing.com Australia
Scynexis CEO Angulo Gonzalez buys $100k in shares - Investing.com
SCYNEXIS (SCYX) CEO joins private placement, adds stock and warrants - Stock Titan
SCYNEXIS, Inc. (SCYX) stock price, news, quote and history - Yahoo Finance UK
SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD TherapeuticsSlideshow (NASDAQ:SCYX) 2026-04-01 - seekingalpha.com
SCYNEXIS raises $40 million in private placement financing By Investing.com - Investing.com South Africa
SCYNEXIS acquires SCY-770 for rare kidney disease treatment By Investing.com - Investing.com South Africa
SCYNEXIS Acquires SCY-770, Refocuses on Rare Kidney Disease - TipRanks
SCYX Should I Buy - Intellectia AI
SCYNEXIS (SCYX) extends cash runway to 2029 with $40M PIPE and SCY-770 ADPKD deal - Stock Titan
SCYNEXIS Acquires PXL-770 (SCY-770) to Advance Innovative ADPKD Therapy with Phase 2 Trial Planned for 2026 - Minichart
SCYNEXIS Announces $40 Million Private Placement to Fund SCY-770 Development for Rare Kidney Disease - Minichart
Why did SCYX stock jump 10% in pre-market today? - MSN
SCYNEXIS Acquires AMPK Program, Expands Rare Disease Pipeline - TipRanks
SCYNEXIS Raises $40 Million in Strategic Private Placement - TipRanks
SCYX to Acquire Poxel's PXL770, Targeting ADPKD Treatment Market - GuruFocus
SCYX: Acquisition of SCY-770 enables rapid entry into rare renal disease with strong clinical and commercial prospects - TradingView
Poxel Sells Kidney‑Disease Drug Candidate to Scynexis for Up to $196 Million - Contract Pharma
SCYNEXIS Acquires Novel AMPK Activator for Polycystic Kidney Disease - National Today
Scynexis (SCYX) Secures Acquisition of Innovative Kidney Disease Treatment - GuruFocus
SCYNEXIS Raises $40M in Private Placement - National Today
SCYNEXIS Inc Corporate Update Call Transcript - GuruFocus
SCYNEXIS Acquires Promising ADPKD Therapy PXL-770 - National Today
Scynexis (SCYX) Secures $40M Through Private Placement Agreement - GuruFocus
SCYNEXIS Enters $40 Million Private Placement, Completes Acquisition of PXL-770 to Treat Kidney Disease - MarketScreener
Scynexis In Spotlight After Poxel Deal, $40 Million Private Placement – SCYX Stock Climbs 2% Pre-Market - Stocktwits
Press Release: Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million - Moomoo
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million - Business Wire
Scynexis (NASDAQ: SCYX) prices $40M equity private placement with warrants - Stock Titan
Scynexis Acquires Poxel's AMPK Activator Program, Paying $8M Upfront Plus Up To $188M Milestones - TradingView
SCYNEXIS raises $40 million in private placement financing - Investing.com
SCYNEXIS acquires SCY-770 for rare kidney disease treatment - Investing.com
Scynexis (NASDAQ: SCYX) buys SCY-770 kidney drug for $8M upfront - Stock Titan
SCYNEXIS Announces $40.0 Million Private Placement - The Manila Times
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Bitget
SCYX: Acquisition of SCY-770 targets ADPKD, expanding the rare disease portfolio with a novel therapy - TradingView
SCYNEXIS lands cash to fund rare disease drug work into mid-2029 - Stock Titan
Kidney disease drug with Phase 2 study due this year joins SCYNEXIS - Stock Titan
Scynexis Jumps on SCY-770 Deal — But Volume Tells a Cautious Story - Bitget
SCYNEXIS, Inc. announced that it expects to receive $40.019125 million in funding - MarketScreener
First Participants Dosed in Phase Trial of SCY-247, Building on Oral Formulation Success - Contagion Live
If You Invested $1,000 in Scynexis (SCYX) - Stock Titan
SCYNEXIS (NASDAQ:SCYX) Rating Lowered to “Hold” at Wall Street Zen - Defense World
Published on: 2026-03-22 14:13:05 - baoquankhu1.vn
EBIT per share of SCYNEXIS, Inc. – LSE:0L49 - TradingView
SCYNEXIS (SCYX) Price Target Decreased by 21.43% to 3.74 - MSN
SCYNEXIS, Inc. (SCYX) announces first participants dosed in phase 1 trial of SCY-247 antifungal therapy - MSN
SCYX SEC FilingsScynexis 10-K, 10-Q, 8-K Forms - Stock Titan
SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal Therapy - Insider Monkey
Brookline Capital cuts SCYNEXIS stock price target on valuation By Investing.com - in.investing.com
Brookline Capital cuts SCYNEXIS stock price target on valuation - Investing.com Nigeria
Scynexis Inc Azioni (SCYX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):